The 2017 ASCP Annual Meeting was in Miami Beach, FL from May 29 - June 2, 2017. The meeting included representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry that discussed key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Marlene Freeman and John Newcomer with representation of the sectors that are part of the ASCP community led the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprised the 2017 Steering Committee. A Program Committee under the leadership of Drs. Holly Swartz and Alan Gelenberg were responsible for the review of all program submissions.

We look forward to seeing you in Miami Beach in 2018!